Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Juegang Ju"'
Autor:
Anisha B Patel, Milan J. Anadkat, Omkar Subhash Marathe, Mark L Webb, Robert Claude Tyler, Wenhui Zhang, Chengguang Wu, Juegang Ju, Hong Tang, Jie Luo, Mario E. Lacouture
Publikováno v:
Journal of Clinical Oncology. 41:TPS741-TPS741
TPS741 Background: Hand-foot skin reaction (HFSR) is associated with the use of multi-targeted tyrosine kinase inhibitors sharing vascular endothelial growth factor receptor inhibitor (VEGFRi) activity (e.g., cabozantinib, regorafenib, sorafenib, sun
Autor:
Mario E. Lacouture, Milan J. Anadkat, Anisha B Patel, Omkar Subhash Marathe, Mark L Webb, Robert Claude Tyler, Liping Chen, Chengguang Wu, Wenxi Li, Juegang Ju, Jie Luo, Hong Tang, Nicholas J. Vogelzang
Publikováno v:
Journal of Clinical Oncology. 40:e24083-e24083
e24083 Background: EGFRi’s are associated with dermatologic AEs that include an acneiform skin rash. This rash occurs in up to 80% for all grades and 18% for grades ≥3. Treatments are based on grade and include topical antibiotics or corticostero
Autor:
Mario E. Lacouture, Milan J. Anadkat, Anisha B Patel, Omkar Subhash Marathe, Mark L Webb, Robert Claude Tyler, Liping Chen, Chengguang Wu, Wenxi Li, Juegang Ju, Jie Luo, Hong Tang, Nicholas J. Vogelzang
Publikováno v:
Journal of Clinical Oncology. 40:322-322
322 Background: VEGFRi therapies are associated with hand-foot skin reaction (HFSR) that affects up to 69% of patients depending on the VEGFRi administered. The incidence and severity of HFSR are dose-dependent and have been associated with improved
Autor:
Mario E. Lacouture, Anisha B Patel, Nicole R. LeBoeuf, Omkar Subhash Marathe, Jonathan Leventhal, Jennifer N. Choi, Elaine Tat Lam, Benjamin S. Kaffenberger, Martin H Voss, Mark L Webb, Robert Claude Tyler, Juegang Ju, Hong Tang, Jie Luo, Milan J. Anadkat, Nicholas J. Vogelzang
Publikováno v:
Journal of Clinical Oncology. 40:TPS396-TPS396
TPS396 Background: Hand-foot skin reaction (HFSR) is associated with the use of multi-targeted tyrosine kinase inhibitors sharing vascular endothelial growth factor receptor inhibitory (VEGFRi) activity (e.g., cabozantinib, regorafenib, sorafenib, su
Autor:
Omkar Subhash Marathe, Lina Tang, Robert C Tyler, Mark L Webb, Liping Chen, Chengguang Wu, Wenxi Li, Juegang Ju, Jie Luo, Hong Tang, Nicholas J. Vogelzang
Publikováno v:
Journal of Clinical Oncology. 40:76-76
76 Background: Chemotherapy and targeted therapies are associated with GI toxicities including diarrhea that affects 50% to 80% of patients. Severe complications include dehydration, malnutrition, fatigue, renal insufficiency, and systemic infection.
Autor:
Mark L. Webb, Mario E. Lacouture, Elaine T. Lam, Anisha B. Patel, Benjamin H. Kaffenberger, Jennifer N. Choi, Robert Claude Tyler, Juegang Ju, Nicholas J. Vogelzang, Jie Luo, Hong Tang, Milan J. Anadkat, Omkar Subhash Marathe
Publikováno v:
Journal of Clinical Oncology. 39:TPS12132-TPS12132
TPS12132 Background: Hand-Foot Skin Reaction (HFSR) is frequently associated with the use of multi-targeted tyrosine kinase inhibitors of the vascular endothelial growth factor receptor (VEGFRi) such as cabozantinib, regorafenib, sunitinib, and lenva
Autor:
Juegang Ju, Sheng-tian Li
Publikováno v:
Neural Regeneration Research; Feb2011, Vol. 6 Issue 2, p10-10, 1p